Reading size

PACK IN HAND · ONE-PAGE CHECK

Medicine pack check sheet

Print this sheet or fill it in before speaking with a pharmacist or clinician. Copy only what is printed on the pack in hand. The published fields below are starting points from this record, not proof that your pack is the same product.

Published record starting point

Record display name
SUPRAX
Generic name / active ingredient
cefixime
Dosage-form class
Dosage form and presentation as documented in the linked primary label
Route
Oral
Record reviewed
2026-08-31

Copy from the pack in hand

Source-linked reading points

  • 400 mg is the labelled amount in each capsule; 500 mg/5 mL is the concentration after suspension reconstitution. A similar total milligram number does not make capsule and liquid self-convertible, interchangeable, divisible or suitable for making up a missed use.
  • The same DailyMed label lists 100 mg/5 mL, 200 mg/5 mL and 500 mg/5 mL suspension concentrations. Any order expressed in mL must also identify the exact concentration; the site will not derive a personal prescription from millilitres, age or weight.
  • Tell the prescriber about previous reactions to cefixime, other cephalosporins or penicillins. Breathing difficulty, facial or throat swelling, fainting, widespread rash or another severe allergic feature requires immediate local emergency care.
  • Severe, persistent or bloody diarrhoea, marked abdominal pain, fever, dehydration or weakness needs prompt medical assessment. The label explains that the problem can appear after antibacterial treatment has ended. Do not self-use an antidiarrhoeal medicine to mask severe symptoms.

Reviewed presentation examples — compare every field

  • Cefixime 400 mg per capsule; 50-capsule bottleNDC 27437-208-08
  • Cefixime 400 mg per capsule; 10-capsule unit-dose blister packNDC 27437-208-11
  • Cefixime 500 mg per 5 mL after reconstitution as labelled; 10 mL bottleNDC 27437-207-02
  • Cefixime 500 mg per 5 mL after reconstitution as labelled; 20 mL bottleNDC 27437-207-03

EDITORIAL RECORD

Who prepared and checked this page

Byline
OriginDrug Content Editorial
Review role
Public primary-source verification
Last reviewed
2026-08-31
Source record
4 clickable primary-source entry points are listed with this dossier.

The review role checks source traceability, stated market, document version and product-identity fields. It is not a claim of clinical licensure, prescribing authority or individual pharmacy service. Read the editorial policy.

Search records
Enlarged public-label image